Acumen Pharmaceuticals Inc <ABOS.OQ> expected to post a loss of 54 cents a share - Earnings Preview
Acumen Pharmaceuticals Inc ABOS.OQ ABOS.O is expected to show no change in quarterly revenue when it reports results on May 13 for the period ending March 31 2025
LSEG's mean analyst estimate for Acumen Pharmaceuticals Inc is for a loss of 54 cents per share.
The current average analyst rating on the shares is "strong buy" and the breakdown of recommendations is 6 "strong buy" or "buy," no "hold" and no "sell" or "strong sell."
The mean earnings estimate of analysts was unchanged in the last three months.
Wall Street's median 12-month price target for Acumen Pharmaceuticals Inc is $10.00, above its last closing price of $1.00.
Previous quarterly performance (using preferred earnings measure in US dollars).
QUARTER ENDING | STARMINESMARTESTIMATE® | LSEG IBES ESTIMATE | ACTUAL | BEAT, MET, MISSED | SURPRISE % |
Dec. 31 2024 | -0.48 | -0.62 | Missed | -29.2 | |
Sep. 30 2024 | -0.41 | -0.36 | -0.50 | Missed | -37 |
Jun. 30 2024 | -0.28 | -0.28 | -0.34 | Missed | -21.4 |
Mar. 31 2024 | -0.26 | -0.26 | -0.25 | Beat | 3.8 |
Dec. 31 2023 | -0.30 | -0.26 | -0.28 | Missed | -7.7 |
Sep. 30 2023 | -0.27 | -0.27 | -0.24 | Beat | 9.8 |
Jun. 30 2023 | -0.34 | -0.35 | -0.28 | Beat | 19.1 |
Mar. 31 2023 | -0.35 | -0.35 | -0.28 | Beat | 19.1 |
This summary was machine generated May 9 at 16:26 GMT. All figures in US dollars unless otherwise stated. (For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact RefinitivNewsSupport@thomsonreuters.com)
Related Articles
Meta’s Big Bet: Soaring Profits, Sky-High Risks
TradingKey - Meta's (META) Q1 2025 earnings come in with the world watching in scrutiny. The company has established itself as a platform that exists at the intersection of AI infrastructure, hardware innovation, and next-wave advertising.
Understanding the U.S. Fiscal Framework: Is Trump’s Tariff-for-Tax-Cut Strategy Viable?
TradingKey – With the U.S. Senate and House of Representatives passing the budget resolution for President Donald Trump's second administration (Trump 2.0), his fiscal blueprint—centered on tax cuts, slashing government spending, and debt reduction—is moving forward. However, with federal debt at...
Will the New Taiwan Dollar’s Surge Continue? Likely Not!
TradingKey - Recent internal and external factors have driven a sharp appreciation of the New Taiwan Dollar (TWD). Looking ahead, despite potential pressure from the U.S., Taiwan’s export-oriented economy, emerging economic weakness, and China’s monetary easing ....jpg)
